Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: RSLS =MC$2 M--Cash $7.7 M-- O/S 353 K --Marketed Obesity

No earlier versions found for this Subject.

Return to RSLS =MC$2 M--Cash $7.7 M-- O/S 353 K --Marketed Obesity

RSLS =MC $2.5 M Cash $7.7M / O/S 353 K most of these shares owned by Armistice who still continue buying more current Float is only 100 Kshares . this SUPER EXTREME low float is close to profitability . Lap band to treat Obesity is marketed international. This unknown gem is a potential $100 stock trading at laughable $6 .A MONSTER Opp here guys

ReShape Lifesciences, Inc. is a developer of minimally invasive medical devices to treat obesity and metabolic diseases. Our current portfolio includes the LAP-BAND® Adjustable Gastric Banding System and the ReShape VestTM*, an investigational device, to help treat more patients with obesity.

Reshape Lifescience (RSLS)

Market Cap: $2.5 M
Cash: $7.7 M
Price $6

Shares Out: 353 K -- Armistice alone holding over 200K Shares

Revenue expected to be around $15 million --Product Lap band aquired december 2018 -- lap Band was owned by Allergan at its Peak the product hit almost $300 Million

MASSIVE insider buying
secform4.com

presentation
ir.reshapelifesciences.com

•Acquired in December 2018
•Global regulatory approval
•Only obesity device reimbursed in U.S.

•High-margin product, maintained ASP
•Focus commercial organization on strategic markets for LAP-BAND® •Drive revenue utilizing new long-term clinical data and patient marketing
•Achieve revenues and profits to meet criteria for NASDAQ listing